A citation-based method for searching scientific literature

Charles D Blanke, George D Demetri, Margaret von Mehren, Michael C Heinrich, Burton Eisenberg, Jonathan A Fletcher, Christopher L Corless, Christopher D M Fletcher, Peter J Roberts, Daniela Heinz, Elisabeth Wehre, Zariana Nikolova, Heikki Joensuu. J Clin Oncol 2008
Times Cited: 672







List of co-cited articles
559 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Charles D Blanke, Annick D Van den Abbeele, Burton Eisenberg, Peter J Roberts, Michael C Heinrich, David A Tuveson, Samuel Singer, Milos Janicek,[...]. N Engl J Med 2002
48

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
S Hirota, K Isozaki, Y Moriyama, K Hashimoto, T Nishida, S Ishiguro, K Kawano, M Hanada, A Kurata, M Takeda,[...]. Science 1998
40

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
George D Demetri, Peter Reichardt, Yoon-Koo Kang, Jean-Yves Blay, Piotr Rutkowski, Hans Gelderblom, Peter Hohenberger, Michael Leahy, Margaret von Mehren, Heikki Joensuu,[...]. Lancet 2013
751
39

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
George D Demetri, Allan T van Oosterom, Christopher R Garrett, Martin E Blackstein, Manisha H Shah, Jaap Verweij, Grant McArthur, Ian R Judson, Michael C Heinrich, Jeffrey A Morgan,[...]. Lancet 2006
38

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Jaap Verweij, Paolo G Casali, John Zalcberg, Axel LeCesne, Peter Reichardt, Jean-Yves Blay, Rolf Issels, Allan van Oosterom, Pancras C W Hogendoorn, Martine Van Glabbeke,[...]. Lancet 2004
35

PDGFRA activating mutations in gastrointestinal stromal tumors.
Michael C Heinrich, Christopher L Corless, Anette Duensing, Laura McGreevey, Chang-Jie Chen, Nora Joseph, Samuel Singer, Diana J Griffith, Andrea Haley, Ajia Town,[...]. Science 2003
27

Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Charles D Blanke, Cathryn Rankin, George D Demetri, Christopher W Ryan, Margaret von Mehren, Robert S Benjamin, A Kevin Raymond, Vivien H C Bramwell, Laurence H Baker, Robert G Maki,[...]. J Clin Oncol 2008
693
24

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Ronald P Dematteo, Karla V Ballman, Cristina R Antonescu, Robert G Maki, Peter W T Pisters, George D Demetri, Martin E Blackstein, Charles D Blanke, Margaret von Mehren, Murray F Brennan,[...]. Lancet 2009
865
23

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Michael C Heinrich, Robert G Maki, Christopher L Corless, Cristina R Antonescu, Amy Harlow, Diana Griffith, Ajia Town, Arin McKinley, Wen-Bin Ou, Jonathan A Fletcher,[...]. J Clin Oncol 2008
491
19

Gastrointestinal stromal tumours: origin and molecular oncology.
Christopher L Corless, Christine M Barnett, Michael C Heinrich. Nat Rev Cancer 2011
479
19

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Michael C Heinrich, Christopher L Corless, George D Demetri, Charles D Blanke, Margaret von Mehren, Heikki Joensuu, Laura S McGreevey, Chang-Jie Chen, Annick D Van den Abbeele, Brian J Druker,[...]. J Clin Oncol 2003
19


Gastrointestinal stromal tumors: pathology and prognosis at different sites.
Markku Miettinen, Jerzy Lasota. Semin Diagn Pathol 2006
18

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.
Heikki Joensuu, Aki Vehtari, Jaakko Riihimäki, Toshirou Nishida, Sonja E Steigen, Peter Brabec, Lukas Plank, Bengt Nilsson, Claudia Cirilli, Chiara Braconi,[...]. Lancet Oncol 2012
498
18

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran,[...]. JAMA 2012
576
17

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
Michael C Heinrich, Christopher L Corless, Charles D Blanke, George D Demetri, Heikki Joensuu, Peter J Roberts, Burton L Eisenberg, Margaret von Mehren, Christopher D M Fletcher, Katrin Sandau,[...]. J Clin Oncol 2006
556
17

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
Christopher L Corless, Arin Schroeder, Diana Griffith, Ajia Town, Laura McGreevey, Patina Harrell, Sharon Shiraga, Troy Bainbridge, Jason Morich, Michael C Heinrich. J Clin Oncol 2005
548
15

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H Joensuu, P J Roberts, M Sarlomo-Rikala, L C Andersson, P Tervahartiala, D Tuveson, S Silberman, R Capdeville, S Dimitrijevic, B Druker,[...]. N Engl J Med 2001
14


Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Cristina R Antonescu, Peter Besmer, Tianhua Guo, Knarik Arkun, Glory Hom, Beata Koryotowski, Margaret A Leversha, Philip D Jeffrey, Diann Desantis, Samuel Singer,[...]. Clin Cancer Res 2005
568
14


Gastrointestinal stromal tumour.
Heikki Joensuu, Peter Hohenberger, Christopher L Corless. Lancet 2013
304
13

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.
R P DeMatteo, J J Lewis, D Leung, S S Mudan, J M Woodruff, M F Brennan. Ann Surg 2000
13

Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial.
Jean-Yves Blay, César Serrano, Michael C Heinrich, John Zalcberg, Sebastian Bauer, Hans Gelderblom, Patrick Schöffski, Robin L Jones, Steven Attia, Gina D'Amato,[...]. Lancet Oncol 2020
63
20

Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
B Liegl, I Kepten, C Le, M Zhu, G D Demetri, M C Heinrich, C D M Fletcher, C L Corless, J A Fletcher. J Pathol 2008
283
12

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Michael C Heinrich, Kouros Owzar, Christopher L Corless, Donna Hollis, Ernest C Borden, Christopher D M Fletcher, Christopher W Ryan, Margaret von Mehren, Charles D Blanke, Cathryn Rankin,[...]. J Clin Oncol 2008
404
12

Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Chun-Yan Du, Ye Zhou, Chun Song, Yong-Peng Wang, Zhi-Gang Jie, Yu-Long He, Xiao-Bo Liang, Hui Cao, Zhong-Shu Yan, Ying-Qiang Shi. Eur J Cancer 2014
54
20

Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).
S Bauer, P Rutkowski, P Hohenberger, R Miceli, E Fumagalli, J A Siedlecki, B-P Nguyen, M Kerst, M Fiore, P Nyckowski,[...]. Eur J Surg Oncol 2014
76
14

Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies.
Kjetil Søreide, Oddvar M Sandvik, Jon Arne Søreide, Vanja Giljaca, Andrea Jureckova, V Ramesh Bulusu. Cancer Epidemiol 2016
205
11

Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.
George D Demetri, Yanfeng Wang, Elisabeth Wehrle, Amy Racine, Zariana Nikolova, Charles D Blanke, Heikki Joensuu, Margaret von Mehren. J Clin Oncol 2009
247
11

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
Yoon-Koo Kang, Min-Hee Ryu, Changhoon Yoo, Baek-Yeol Ryoo, Hyun Jin Kim, Jong Jin Lee, Byung-Ho Nam, Nikhil Ramaiya, Jyothi Jagannathan, George D Demetri. Lancet Oncol 2013
107
11

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Maria Debiec-Rychter, Raf Sciot, Axel Le Cesne, Marcus Schlemmer, Peter Hohenberger, Allan T van Oosterom, Jean-Yves Blay, Serge Leyvraz, Michel Stul, Paolo G Casali,[...]. Eur J Cancer 2006
608
11

Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial.
Christopher L Corless, Karla V Ballman, Cristina R Antonescu, Violetta Kolesnikova, Robert G Maki, Peter W T Pisters, Martin E Blackstein, Charles D Blanke, George D Demetri, Michael C Heinrich,[...]. J Clin Oncol 2014
160
11

Diagnosis of gastrointestinal stromal tumors: A consensus approach.
Christopher D M Fletcher, Jules J Berman, Christopher Corless, Fred Gorstein, Jerzy Lasota, B Jack Longley, Markku Miettinen, Timothy J O'Leary, Helen Remotti, Brian P Rubin,[...]. Hum Pathol 2002
11

Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants.
Bryan D Smith, Michael D Kaufman, Wei-Ping Lu, Anu Gupta, Cynthia B Leary, Scott C Wise, Thomas J Rutkoski, Yu Mi Ahn, Gada Al-Ani, Stacie L Bulfer,[...]. Cancer Cell 2019
65
16

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Michael C Heinrich, Robin L Jones, Margaret von Mehren, Patrick Schöffski, César Serrano, Yoon-Koo Kang, Philippe A Cassier, Olivier Mir, Ferry Eskens, William D Tap,[...]. Lancet Oncol 2020
59
18

Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.
Chandrajit P Raut, Matthew Posner, Jayesh Desai, Jeffrey A Morgan, Suzanne George, David Zahrieh, Christopher D M Fletcher, George D Demetri, Monica M Bertagnolli. J Clin Oncol 2006
291
10


Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors (GIST): the EORTC STBSG experience.
Piotr Rutkowski, Alessandro Gronchi, Peter Hohenberger, Sylvie Bonvalot, Patrick Schöffski, Sebastian Bauer, Elena Fumagalli, Pawel Nyckowski, Buu-Phuc Nguyen, Jan Martijn Kerst,[...]. Ann Surg Oncol 2013
119
10

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Olivier Mir, Claire Cropet, Maud Toulmonde, Axel Le Cesne, Mathieu Molimard, Emmanuelle Bompas, Philippe Cassier, Isabelle Ray-Coquard, Maria Rios, Antoine Adenis,[...]. Lancet Oncol 2016
60
16

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
Suzanne George, Qian Wang, Michael C Heinrich, Christopher L Corless, Meijun Zhu, James E Butrynski, Jeffrey A Morgan, Andrew J Wagner, Edwin Choy, William D Tap,[...]. J Clin Oncol 2012
170
10

A precision therapy against cancers driven by KIT/PDGFRA mutations.
Erica K Evans, Alexandra K Gardino, Joseph L Kim, Brian L Hodous, Adam Shutes, Alison Davis, Xing Julia Zhu, Oleg Schmidt-Kittler, Doug Wilson, Kevin Wilson,[...]. Sci Transl Med 2017
75
13

Gastrointestinal Stromal Tumors.
Margaret von Mehren, Heikki Joensuu. J Clin Oncol 2018
97
10

Complementary activity of tyrosine kinase inhibitors against secondary kit mutations in imatinib-resistant gastrointestinal stromal tumours.
César Serrano, Adrián Mariño-Enríquez, Derrick L Tao, Julia Ketzer, Grant Eilers, Meijun Zhu, Channing Yu, Aristotle M Mannan, Brian P Rubin, George D Demetri,[...]. Br J Cancer 2019
47
21

Incidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testing.
Françoise Ducimetière, Antoine Lurkin, Dominique Ranchère-Vince, Anne-Valérie Decouvelaere, Michel Péoc'h, Luc Istier, Philippe Chalabreysse, Christine Muller, Laurent Alberti, Pierre-Paul Bringuier,[...]. PLoS One 2011
291
9

Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Annette Reichardt, Jörg T Hartmann, Daniel Pink, Giuliano Ramadori, Peter Hohenberger, Salah-Eddin Al-Batran, Marcus Schlemmer,[...]. J Clin Oncol 2016
105
9

Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era--a population-based study in western Sweden.
Bengt Nilsson, Per Bümming, Jeanne M Meis-Kindblom, Anders Odén, Aydin Dortok, Bengt Gustavsson, Katarzyna Sablinska, Lars-Gunnar Kindblom. Cancer 2005
834
9

Switch Control Inhibition of KIT and PDGFRA in Patients With Advanced Gastrointestinal Stromal Tumor: A Phase I Study of Ripretinib.
Filip Janku, Albiruni R Abdul Razak, Ping Chi, Michael C Heinrich, Margaret von Mehren, Robin L Jones, Kristen Ganjoo, Jonathan Trent, Hans Gelderblom, Neeta Somaiah,[...]. J Clin Oncol 2020
18
50

KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.
Heikki Joensuu, Piotr Rutkowski, Toshirou Nishida, Sonja E Steigen, Peter Brabec, Lukas Plank, Bengt Nilsson, Chiara Braconi, Andrea Bordoni, Magnus K Magnusson,[...]. J Clin Oncol 2015
85
9

Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132.
Dian Wang, Qiang Zhang, Charles D Blanke, George D Demetri, Michael C Heinrich, James C Watson, John P Hoffman, Scott Okuno, John M Kane, Margaret von Mehren,[...]. Ann Surg Oncol 2012
108
8


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.